Acute Effects of rhBNP in Patients With PH Associated With Acute Exacerbation of Chronic Pulmonary Disease

• Status: Completed
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the acute effect of recombinant human brain natriuretic peptide(rhBNP) on pulmonary hypertension of acute exacerbations of chronic pulmonary disease. rhBNP was administered as a continuous infusion for 24 hours , pulmonary artery pressure and other hemodynamic parameters were monitored by Swan- Ganz catheter.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: LI ZHAO
• Treatments: Natriuretic Peptide, Brain

Criteria

Inclusion Criteria:

1. age>18 years old, male or female;

2. in acute exacerbation period and with a history of chronic respiratory diseases;

3. cardiac ultrasound showed a pulmonary hypertension ≥50mmHg;

4. grade II or WHO grade of heart function;

5. signed informed consent.

Exclusion Criteria:

1. pulmonary hypertension not associated with chronic lung disease;

2. Acute or severe chronic left heart failure;

3. severe respiratory failure during receipt of non-invasive or invasive ventilator therapy;

4. mPAP≤25mmHg or pulmonary capillary wedge pressure (PCWP) ≥15mmHg at rest as assessed by Swan- Ganz catheter;

5. a high risk of hypotension (systolic pressure <100 mmHg or 110 mmHg with the use of intravenous nitroglycerin);

6. Uncontrolled arterial hypertension;

7. acute coronary syndrome;

8. Severe left ventricular hypertrophy;

9. Congenital or acquired valvular or myocardial disease;

10. end-stage renal disease during receipt of renal replacement therapy;

11. clinically significant anemia;

12. other contraindications for vasodilators;

13. treatment with dobutamine (at a dose ≥5 μg per kilogram of body weight per minute);

14. treatment with milrinone or levosimendan within the previous 30 days.